PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27208026-1 2016 Effect of Captopril, Losartan, and Bradykinin on Early Steps of Insulin Action. Losartan 21-29 insulin Homo sapiens 64-71 31336455-10 2019 Drugs that had more interaction with insulin were: acetylsalicylic acid (40%), enalapril (18%), losartan (32%) and hydrochlorothiazide (23%). Losartan 96-104 insulin Homo sapiens 37-44 27651716-0 2016 Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients. Losartan 10-18 insulin Homo sapiens 35-42 26763851-1 2016 The objective of this study was to observe the antihypertensive effect of losartan and levamlodipine besylate on insulin resistance in patients with essential hypertension (EH) combined with isolated impaired fasting glucose (i-IFG). Losartan 74-82 insulin Homo sapiens 113-120 26763851-8 2016 The antihypertensive effect of losartan and levamlodipine besylate could amoliorate insulin resistance in patients with EH combined with i-IFG. Losartan 31-39 insulin Homo sapiens 84-91 26763851-9 2016 The improvement of insulin resistance by losartan potassium at 12 months might be better than that by levamlodipine besylate; however, after 24 and 36 months of follow-up, both agents significantly alleviated insulin resistance. Losartan 41-59 insulin Homo sapiens 19-26 25994603-1 2015 The aim of this study was to evaluate the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. Losartan 65-73 insulin Homo sapiens 145-152 26104969-0 2016 Efficacy of losartan for improving insulin resistance and vascular remodeling in hemodialysis patients. Losartan 12-20 insulin Homo sapiens 35-42 26104969-3 2016 In the present study, we investigated the effects of the Ang II receptor blocker losartan on insulin resistance, arterial stiffness, and carotid artery structure in hemodialysis patients. Losartan 81-89 insulin Homo sapiens 93-100 26104969-12 2016 With comparable BP-lowering efficacy, losartan achieved better improvement in insulin sensitivity, arterial stiffness, and carotid artery hypertrophy in hemodialysis patients. Losartan 38-46 insulin Homo sapiens 78-85 27440952-0 2016 Effect of losartan and atenolol on insulin sensitivity in nondiabetic hypertensive patients. Losartan 10-18 insulin Homo sapiens 35-42 27440952-6 2016 CONCLUSIONS: Losartan improved the insulin sensitivity while atenolol worsened it. Losartan 13-21 insulin Homo sapiens 35-42 25994603-12 2015 In addition to providing a greater BP reduction, barnidipine+losartan improved the insulin sensitivity, as assessed by an euglycemic hyperinsulinemic clamp, and improved some of the adipocytokines related to insulin resistance. Losartan 61-69 insulin Homo sapiens 83-90 25994603-12 2015 In addition to providing a greater BP reduction, barnidipine+losartan improved the insulin sensitivity, as assessed by an euglycemic hyperinsulinemic clamp, and improved some of the adipocytokines related to insulin resistance. Losartan 61-69 insulin Homo sapiens 138-145 23154622-9 2013 CONCLUSIONS: On the 75 g OGTT, 50 mg Losartan with 12.5 mg HCTZ combinations did not worsen glucose tolerance; moreover, they improved BP, insulin resistance and sensitivity in non-DM Japanese patients with essential hypertension uncontrolled with ARBs alone. Losartan 37-45 insulin Homo sapiens 139-146 25502581-0 2015 Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Losartan 0-8 insulin Homo sapiens 17-24 25502581-0 2015 Losartan reduces insulin resistance by inhibiting oxidative stress and enhancing insulin signaling transduction. Losartan 0-8 insulin Homo sapiens 81-88 23299501-0 2013 Losartan increases muscle insulin delivery and rescues insulin"s metabolic action during lipid infusion via microvascular recruitment. Losartan 0-8 insulin Homo sapiens 26-33 23299501-9 2013 Lipid infusion abolished insulin-mediated increases in muscle MBV and MBF and lowered insulin-stimulated whole body glucose disposal (P = 0.0001), which were reversed by losartan administration. Losartan 170-178 insulin Homo sapiens 25-32 23299501-9 2013 Lipid infusion abolished insulin-mediated increases in muscle MBV and MBF and lowered insulin-stimulated whole body glucose disposal (P = 0.0001), which were reversed by losartan administration. Losartan 170-178 insulin Homo sapiens 86-93 25502581-7 2015 Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced. Losartan 132-140 insulin Homo sapiens 46-53 25502581-7 2015 Compared with amlodipine group, fasting blood insulin levels and insulin resistance index (HOMA-IR) were significantly decreased in losartan group, and in addition, the circulating levels of 8-OHdG and NT were significantly decreased in losartan group, while the serum SOD activity was enhanced. Losartan 132-140 insulin Homo sapiens 65-72 25502581-12 2015 CONCLUSIONS: These results suggest that the effect of losartan on insulin resistance is associated with the reduction of oxidative stress and inflammation in patients with type 2 DKD as well as the activation of insulin signal pathway in insulin-resistance 3T3-L1 adipocytes through modulation of PI3K pathway. Losartan 54-62 insulin Homo sapiens 66-73 25502581-12 2015 CONCLUSIONS: These results suggest that the effect of losartan on insulin resistance is associated with the reduction of oxidative stress and inflammation in patients with type 2 DKD as well as the activation of insulin signal pathway in insulin-resistance 3T3-L1 adipocytes through modulation of PI3K pathway. Losartan 54-62 insulin Homo sapiens 212-219 25502581-12 2015 CONCLUSIONS: These results suggest that the effect of losartan on insulin resistance is associated with the reduction of oxidative stress and inflammation in patients with type 2 DKD as well as the activation of insulin signal pathway in insulin-resistance 3T3-L1 adipocytes through modulation of PI3K pathway. Losartan 54-62 insulin Homo sapiens 212-219 22051059-0 2012 Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension. Losartan 11-19 insulin Homo sapiens 64-71 22051059-3 2012 We hypothesized that the angiotensin receptor antagonist losartan would improve insulin-mediated vasodilation, and thereby improve insulin-stimulated glucose uptake in skeletal muscle of insulin-resistant subjects. Losartan 57-65 insulin Homo sapiens 80-87 22051059-3 2012 We hypothesized that the angiotensin receptor antagonist losartan would improve insulin-mediated vasodilation, and thereby improve insulin-stimulated glucose uptake in skeletal muscle of insulin-resistant subjects. Losartan 57-65 insulin Homo sapiens 131-138 22051059-3 2012 We hypothesized that the angiotensin receptor antagonist losartan would improve insulin-mediated vasodilation, and thereby improve insulin-stimulated glucose uptake in skeletal muscle of insulin-resistant subjects. Losartan 57-65 insulin Homo sapiens 131-138 22051059-8 2012 Insulin-mediated vasodilation was augmented following both treatments [increase in leg vascular conductance: pretreatment 0.7 +- 0.3 l/min/mmHg (losartan, mean +- SEM) and 0.9 +- 0.3 (placebo), posttreatment 1.0 +- 0.4 (losartan) and 1.3 +- 0.6 (placebo)] but not different between treatment groups (p = 0.53). Losartan 145-153 insulin Homo sapiens 0-7 22051059-8 2012 Insulin-mediated vasodilation was augmented following both treatments [increase in leg vascular conductance: pretreatment 0.7 +- 0.3 l/min/mmHg (losartan, mean +- SEM) and 0.9 +- 0.3 (placebo), posttreatment 1.0 +- 0.4 (losartan) and 1.3 +- 0.6 (placebo)] but not different between treatment groups (p = 0.53). Losartan 220-228 insulin Homo sapiens 0-7 21861845-2 2012 In the present study, we examined the effects of ARB (angiotensin receptor blocker) therapy (losartan, 100 mg/day) on insulin sensitivity and endothelial function in 53 subjects with stage I hypertension, abdominal obesity and impaired fasting glucose. Losartan 93-101 insulin Homo sapiens 118-125 21153603-4 2011 Blocking the actions of Angiotensin II with an AT1 receptor antagonist (Losartan), has beneficial effects in patients with insulin resistance or type 2 diabetes mellitus. Losartan 72-80 insulin Homo sapiens 123-130 21142812-1 2011 Losartan, an angiotensin II receptor blocker (ARB), has been reported to increase serum level of high-molecular weight (HMW) adiponectin, which has beneficial effects on insulin resistance and atherosclerosis. Losartan 0-8 insulin Homo sapiens 170-177 20827028-0 2010 Addition of losartan to angiotensin-converting enzyme inhibitors improves insulin resistance in patients with chronic heart failure treated without beta-blockers. Losartan 12-20 insulin Homo sapiens 74-81 15775796-0 2005 Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. Losartan 25-33 insulin Homo sapiens 59-66 17308317-10 2007 Furthermore, C-peptide concentrations, the insulin sensitivity index, and the insulin-to-glucose ratio were significantly increased after 3 months of therapy with losartan as compared to amlodipine (P<0.05). Losartan 163-171 insulin Homo sapiens 43-50 17308317-10 2007 Furthermore, C-peptide concentrations, the insulin sensitivity index, and the insulin-to-glucose ratio were significantly increased after 3 months of therapy with losartan as compared to amlodipine (P<0.05). Losartan 163-171 insulin Homo sapiens 78-85 17308317-11 2007 Reductions of fasting insulin concentrations and HOMA-IR were also observed for the losartan group; however, reductions were not significant when compared with the amlodipine group. Losartan 84-92 insulin Homo sapiens 22-29 17460371-0 2007 Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Losartan 27-35 insulin Homo sapiens 39-46 16857181-8 2006 CONCLUSION: Serum EC-SOD concentrations may be a sensitive biochemical marker of insulin resistance in patients with type 2 diabetes and hypertension and that losartan improves insulin sensitivity by increasing EC-SOD and adiponectin production and decreasing TNF-alpha production. Losartan 159-167 insulin Homo sapiens 177-184 16982630-6 2006 Furthermore, Ang II abolished insulin-induced tyrosine phosphorylation of insulin receptor substrate 1 (IRS1), activation of protein kinase B (Akt), and glucose transporter-4 (GLUT4) translocation to the plasma membrane, which was reversed by pretreating myotubes with losartan or apocynin. Losartan 269-277 insulin Homo sapiens 30-37 16868143-11 2006 CONCLUSIONS: Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment. Losartan 13-21 insulin Homo sapiens 102-109 16868143-11 2006 CONCLUSIONS: Losartan raised serum levels of free IGF-I, which might contribute to the improvement of insulin resistance associated with losartan treatment. Losartan 137-145 insulin Homo sapiens 102-109 19164322-13 2009 Declines in fasting insulin and HOMA-IR by losartan are accompanied by decreased adiponectin levels, might offer potential protection in humans. Losartan 43-51 insulin Homo sapiens 20-27 16988754-0 2006 Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. Losartan 70-78 insulin Homo sapiens 9-16 15775796-2 2005 We hypothesized that treatment with losartan as compared to atenolol would improve insulin sensitivity through regression of peripheral vascular hypertrophy/rarefaction. Losartan 36-44 insulin Homo sapiens 83-90 15775796-8 2005 CONCLUSIONS: As compared to atenolol, losartan treatment was associated with less peripheral vascular hypertrophy/rarefaction and higher insulin sensitivity. Losartan 38-46 insulin Homo sapiens 137-144 15775796-10 2005 The ability of losartan to preserve insulin sensitivity may explain the lower incidence of new onset diabetes in patients treated with losartan in the LIFE study. Losartan 15-23 insulin Homo sapiens 36-43 15775796-10 2005 The ability of losartan to preserve insulin sensitivity may explain the lower incidence of new onset diabetes in patients treated with losartan in the LIFE study. Losartan 135-143 insulin Homo sapiens 36-43 11725915-0 2001 The effect of Losartan on insulin resistance and beta cell function in chronic hemodialysis patients. Losartan 14-22 insulin Homo sapiens 26-33 11903420-0 2001 Losartan modifies glomerular hyperfiltration and insulin sensitivity in type 1 diabetes. Losartan 0-8 insulin Homo sapiens 49-56 11903420-8 2001 However, the glucose oxidation rate increased significantly after losartan vs. placebo in the basal state (1.72 +/- 0.34 vs. 1.33 +/- 0.18, mg/kg/min, p < 0.01) and during insulin stimulation (2.89 +/- 0.75 vs. 2.40 +/- 0.62 mg/kg/min, p < 0.03). Losartan 66-74 insulin Homo sapiens 175-182 11903420-9 2001 Basal and insulin-stimulated non-oxidative glucose disposal tended to decrease after losartan; however, this was not significant. Losartan 85-93 insulin Homo sapiens 10-17 11903420-12 2001 CONCLUSIONS: Losartan reduces blood pressure, glomerular hyperfiltration and FF, and improves basal and insulin-stimulated glucose oxidation in normotensive, normoalbuminuric type 1 diabetic patients. Losartan 13-21 insulin Homo sapiens 104-111 11695995-7 2001 Losartan prevented angiotensin II inhibition of insulin-induced ERK-1/-2-type MAP kinase activation and 4E-BP1 phosphorylation, suggesting mediation of the effect of angiotensin II by its type 1 receptor. Losartan 0-8 insulin Homo sapiens 48-55 15152291-1 2004 BACKGROUND: The Reduction of Endpoints in NIDDM [non-insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renoprotective effects of losartan in patients with nephropathy from type 2 diabetes. Losartan 125-133 insulin Homo sapiens 53-60 15152291-1 2004 BACKGROUND: The Reduction of Endpoints in NIDDM [non-insulin-dependent diabetes mellitus] with the Angiotensin II Antagonist Losartan (RENAAL) study demonstrated the renoprotective effects of losartan in patients with nephropathy from type 2 diabetes. Losartan 192-200 insulin Homo sapiens 53-60 11236238-0 2000 [The effect of treatment with enalapril versus losartan on levels of insulin resistance in patients with essential hypertension]. Losartan 47-55 insulin Homo sapiens 69-76 9833600-0 1998 Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Losartan 38-46 insulin Homo sapiens 50-57 9833600-1 1998 AIMS: The aim of this study was to compare the effects of the ACE-inhibitor lisinopril and the angiotensin II receptor antagonist losartan on insulin sensitivity in the treatment of non diabetic hypertensives. Losartan 130-138 insulin Homo sapiens 142-149 9781930-1 1998 The aim of this study was to compare the effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril and the angiotensin II antagonist losartan on insulin sensitivity and plasma fibrinogen in overweight hypertensive patients. Losartan 148-156 insulin Homo sapiens 160-167 9205938-0 1997 Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. Losartan 0-8 insulin Homo sapiens 33-40 9554807-2 1998 Therefore the aim of this study was to investigate the effects of the angiotensin II-receptor antagonist losartan on insulin sensitivity, lipid profile, and plasma endothelin-1 (ET-1) levels in normotensive offspring of hypertensive parents with a randomized, double-blind, placebo- controlled, crossover design. Losartan 105-113 insulin Homo sapiens 117-124 9554807-9 1998 The normal insulin sensitivity in the subjects studied might explain why losartan did not improve it. Losartan 73-81 insulin Homo sapiens 11-18 9205938-0 1997 Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. Losartan 0-8 insulin Homo sapiens 131-138 9205938-1 1997 We investigated the possible role of losartan on insulin-mediated glucose uptake, substrate oxidation and blood flow in insulin-resistant hypertensive patients. Losartan 37-45 insulin Homo sapiens 49-56 9205938-10 1997 Insulin-mediated change in blood flow was greater after losartan than placebo administration (111 +/- 4 vs 84 +/- 3%, P < 0.01). Losartan 56-64 insulin Homo sapiens 0-7 9205938-12 1997 Analysis of substrate oxidation revealed that losartan administration improved insulin action and non-oxidative glucose metabolism (NOGM) (30.8 +/- 2.2 vs 22.8 +/- 2.8 mumol/kg FFM x min, P < 0.05). Losartan 46-54 insulin Homo sapiens 79-86 9205938-13 1997 In conclusion losartan improves insulin-mediated glucose uptake through an increase in NOGM and blood flow in hypertensive patients. Losartan 14-22 insulin Homo sapiens 32-39 8069407-7 1994 Thus, antihypertensive treatment with the new selective angiotensin II receptor antagonist Losartan seems to improve insulin sensitivity. Losartan 91-99 insulin Homo sapiens 117-124 8986909-4 1996 RESULTS: Supine blood pressure was reduced from 146 +/- 3/90 +/- 3 mmHg on placebo to 134 +/- 4/83 +/- 3 mmHg on losartan and the difference was maintained during 120 min of insulin infusion and glucose clamping. Losartan 113-121 insulin Homo sapiens 174-181 8583481-0 1995 Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? Losartan 11-19 insulin Homo sapiens 23-30 8794822-0 1996 Effects of losartan on insulin sensitivity in hypertensive subjects. Losartan 11-19 insulin Homo sapiens 23-30 8794822-2 1996 However, the effects of losartan on insulin sensitivity and glucose metabolism have not been investigated in detail. Losartan 24-32 insulin Homo sapiens 36-43 8794822-3 1996 Therefore, we carried out a randomized, double-blind study to compare the effects of losartan (50 mg QD) and metoprolol (95 mg QD) on insulin sensitivity, insulin secretion, glucose tolerance, and lipids and lipoproteins in 20 hyperinsulinemic subjects with essential hypertension. Losartan 85-93 insulin Homo sapiens 134-141 8583481-9 1995 These results suggest that losartan, possibly by a sympathicolytic effect, lowers blood viscosity, causes vasodilation, and improves insulin sensitivity in essential hypertension. Losartan 27-35 insulin Homo sapiens 133-140 7946158-12 1994 Moreover, insulin potentiated the antimitogenic effects of both ACEIs and losartan on HMCs. Losartan 74-82 insulin Homo sapiens 10-17 8069407-1 1994 The objective of this study was to investigate the effect of Losartan (NK-954, DuP-753), a new selective angiotensin II receptor antagonist, on insulin sensitivity and sympathetic nervous system activity in patients with severe primary hypertension. Losartan 61-69 insulin Homo sapiens 144-151 8069407-8 1994 A decrease in plasma noradrenaline on Losartan suggests a sympathicolytic effect which together with vasodilation may explain the fall in blood pressure and the improvement in insulin sensitivity. Losartan 38-46 insulin Homo sapiens 176-183 8466592-3 1993 The insulin effect was only partially inhibited by the converting enzyme inhibitors enalapril, quinapril, and quinaprilat, whereas it was markedly or totally blunted by the angiotensin II antagonists DuP753 and PD123177. Losartan 200-206 insulin Homo sapiens 4-11 15322693-0 2004 Mechanism of improving effect of losartan on insulin sensitivity of non-insulin-dependent diabetes mellitus rats. Losartan 33-41 insulin Homo sapiens 45-52 15322693-1 2004 The specific inhibition of angiotensin II action at AT(1) receptors by losartan has been shown to decrease peripheral insulin resistance in type 2 diabetic patients and animal models. Losartan 71-79 insulin Homo sapiens 118-125 15322693-5 2004 Oral administration of losartan improved insulin sensitivity, which was determined by an oral glucose tolerance test (OGTT). Losartan 23-31 insulin Homo sapiens 41-48 15322693-7 2004 The levels of IRS-1 tyrosine phosphorylation, PI 3-kinase activity associated with IRS-1 and PKB activation after stimulation with insulin in muscle tissue of NIDDM rats were significantly decreased (P<0.01) compared with those in the control rats, while they were not increased by losartan. Losartan 285-293 insulin Homo sapiens 131-138 15322693-8 2004 Losartan had a major effect on GLUT4 translocation in myocytes, as it significantly increased (P<0.05) the insulin-induced amounts of GLUT4 in plasma membrane (PM) and T-tubules (TT) in myocytes from NIDDM rats. Losartan 0-8 insulin Homo sapiens 110-117 15322693-10 2004 Our results suggest that losartan may exert beneficial effects on insulin resistance by increasing the translocation of GLUT4 in muscle tissue, which is probably associated with a non-PI 3-kinase-dependent mechanism. Losartan 25-33 insulin Homo sapiens 66-73